On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The ongoing efforts in COVID antiviral discovery is a stark reminder that small molecule drug discovery is still painfully slow. This is partly because the medicinal chemistry optimisation cycle – designing molecules, synthesising molecules, and feeding data from biological assays into the next round of designs – is still empirically driven. In my talk, I will discuss our progress towards using hypothesis-driven machine learning to close the design-make-test cycle: predicting molecular properties, designing optimised molecules and ensuring the designed molecules are rapidly synthesizable. I will show how physical and chemical understanding can be incorporated into machine learning, enabling data-driven methods to be useful in the low-data limit that most drug discovery campaigns operate in. I will illustrate our approach using examples from COVID Moonshot, an open science drug discovery project that aims to discover oral SARS-CoV-2 main protease inhibitors.
